Galaxy Diagnostics

Website

Galaxy Diagnostics, Inc.

55 Investors
Molecular Diagnostics
RESEARCH TRIANGLE PARK, NC

Galaxy Diagnostics, Inc. specializes in advanced testing solutions designed to detect elusive flea- and tick-borne pathogens, specifically *Bartonella* species, which are often missed by standard diagnostic methods. By enhancing clinical detection, the company aims to improve patient outcomes and strengthen the connection between human and animal health.

Products & Team

Bartonella Digital ePCR™ Platform

DiagnosticsSeed

This platform utilizes droplet digital PCR (ddPCR) alongside the patented Bartonella alphaproteobacteria growth medium (BAPGM™) to effectively enrich samples and directly detect *Bartonella* DNA, leading to enhanced diagnostic sensitivity compared to traditional methods.

Value Proposition

Diagnoses elusive flea- and tick-borne infections that are often overlooked by conventional laboratory tests.

Pain Points

Difficulty in diagnosing vector-borne infections due to sensitivity limitations of traditional diagnostic tests.

High sensitivity with direct detection of *Bartonella* DNACombination of ddPCR and BAPGM™ for effective sample enrichmentApplicable for both human and animal samples

Nicole Bell

Company Signatory
Chief Executive Officerat Galaxy Diagnostics, Inc.
Joined Galaxy Diagnostics, Inc.
April 2025

Joel Kimbrough

Directorat Galaxy Diagnostics, Inc.
Joined Galaxy Diagnostics, Inc.
April 2025
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
RESEARCH TRIANGLE PARK, NC
Primary headquarters

Funding History

Total Raised:
$4.1M
E

Equity Offering

April 2025
$11.2M
Target
Use of Proceeds
Other than the payment of salaries and other compensation and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
Progress
37%
Raised
$4.1M
Target
$11.2M
#000146244425000002